Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β

Weber, Christoph K.; Liptay, Susanne; Wirth, Thomas; Adler, Guido; Schmid, Roland M.

doi:10.1053/gast.2000.19458

Cited by 266 publications

(173 citation statements)

References 29 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…Although the exact mechanism of action of mesalazine has still to be elucidated, several potential mechanisms have been suggested, including 5-aminosalicylate-induced inhibition of inflammation by interfering with the metabolism of arachidonic acid, prevention of mucosal generation of leukotrienes and prostaglandins, scavenging of free radicals and mechanisms only recently identified involving inhibition of nuclear factor-kappaB (NFB) and induction of apoptosis (6,18,31,43,47,48,55,57,59) . Additional relevant properties include changes in the production of immune globulins and diminished production of interleukin-1 and partial inhibition of platelet activating factor (PAF) expression, resulting in a decrease in leucocyte trafficking (32) .…”

Section: Discussionmentioning

confidence: 99%

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Boiocchi

Almeida

Leite

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Results -Compared to baseline, there were statistically significant reduction of symptom score after 30 th day therapy in all three groups: MG (P<0.0001); MSbG (P<0.0001) and in SbG (P = 0.003). There were statistically significant differences in the symptom score at 30 th day therapy of the MG, MSbG and SbG groups (P = 0.03). There were no statistical differences between MSbG and MG symptom score at 30th day therapy (P = 0.9). Conclusions -The use of mesalazine alone, Saccharomyces boulardii alone or combined treatment with mesalasine and Saccaromyces boulardii improved IBS-D symptoms. The improvement of the symptom score was greater with mesalazine alone or combined with Sb as compared with Sb treatment alone. These preliminary results suggest that mezalazine may be useful in treatment of IBS-d patients, and warrant further larger studies. HEADINGS -Irritable bowel syndrome. Diarrhea. Mesalamine. Saccharomyces boulardii.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Boiocchi

Almeida

Leite

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Although its exact mechanism are still unknown (10,20) , several potential mechanisms have been suggested, including 5-aminosalicylate-induced inhibition of inflammation by interfering with the metabolism of arachidonic acid, prevention of mucosal generation of leukotrienes and PG (26) scavenging of free radicals (21,26) and mechanisms only recently identified involving inhibition of nuclear factor-kappaB (NFκB) and induction of apoptosis (4,15,19,27,28) .…”

Section: Discussionmentioning

confidence: 99%

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

Boiocchi

Almeida

Leite

et al. 2011

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. Objective -To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. Methods -Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4).

show abstract

“…Proteosome inhibitors regulates the degradation of IB and hence inhibits NFB, and a few publications have documented their efficacy in triggering apoptosis in cancer cell lines in combination with either chemotherapeiutic drugs or death-inducing cytokines (88)(89)(90). Sulfasalazine and methotrexate are widely used for treatment of acute states of IBD by inhibiting NF-B activation (91,92), thus, may also decrease the risk of developing cancer. NSAIDs and aspirin reduce the risk of gastric cancer in human and the incidence of colorectal cancer in animal models (93,94).…”

Section: Nf-b Inhibition: Strategy For Colorectal Cancer Therapymentioning

confidence: 99%

NF-κB Signaling Pathway, Inflammation and Colorectal Cancer

et al. 2009

View full text Add to dashboard Cite

There is growing evidence for a connection between inflammation and tumor development, and the nuclear factor kappa B (NF-B), a proinflammatory transcription factor, is hypothesized to promote tumorigenesis. Although the genetic evidence for the hypothesis has been lacking, recent papers have lent credence to this hypothesis. It has been reported that constitutive NF-B activation in inflammatory bowel diseases (

show abstract

Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β

Cited by 266 publications

References 29 publications

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

NF-κB Signaling Pathway, Inflammation and Colorectal Cancer

Contact Info

Product

Resources

About